Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 26, 2010

View Archived Issues

New beta-lactamase inhibitor MK-7655 shows promise in preclinical and clinical studies

Cardium Therapeutics reports new findings on Excellagen in wound healing

LNPEP gene SNP is associated with outcome of patients with septic shock

IL-17A-targeted antibody AIN-457 shows promise in psoriasis, rheumatoid arthritis and uveitis

Linifanib monotherapy is active in phase II NSCLC trial

HIV vaccine MV1-F4 induces robust immune response in monkeys

Merck & Co. and Scynexis characterize new efumafungin antifungals

Merck KGaA presents new E-NPP 2 inhibitors

Santhera regains full U.S. and Canadian rights to fipamezole from Biovail

Abbott Cardiovascular Systems claims new HCV polymerase inhibitors

Presidio Pharmaceuticals discovers new inhibitors of HCV NS5A

Abbott discloses new cannabinoid CB2 receptor ligands

FDA approves Warner Chilcott's new oral contraceptive

NeuroVive and to-BBB to codevelop therapies for stroke and other CNS disorders

CHMP recommends marketing authorization for MedImmune's FluEnz vaccine

Cellectis and Kyoto University join forces for stem cell research

CHMP recommends variation of marketing authorization for Pfizer's Sutent

CHMP recommends new indication for Bristol-Myers Squibb's Sprycel

EMA recommends changes in prescribing information for Invirase

Chugai Pharma files for new indication of Pegasys/Copegus combination therapy

AZD-9773 enters phase IIb trial in patients with severe sepsis and/or septic shock

Alkermes' combination therapy for cocaine addiction to advance to phase II

FDA requests additional information from ViroPharma on Cinryze

Genmab begins phase III trial of ofatumumab versus rituximab in follicular NHL

Sanofi-aventis initiates phase III TERACLES trial of teriflunomide in relapsing MS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
HX-16108 holds promise for treating inflammatory skin diseases
BioWorld Science
Atopic dermatitis (AD) is an inflammatory skin disease accompanied by pruritus, for which IL-13 and IL-31 are clinically validated targets. Earendil Labs Inc. has...